跳至主要内容
临床试验/ISRCTN44366049
ISRCTN44366049已完成未知

A multicentre, double-blind, randomised, parallel group, placebo-controlled, dose ranging pilot study of ethyl eicosapentaenoate (EPA) as adjunct therapy in patients who remain depressed following treatment with standard antidepressant therapy

axdale Ltd (UK)0 个研究点目标入组 0 人开始时间: 2002年2月26日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Written informed consent
  • 2. Hamilton score of 14 or more
  • 3. Treatment for =8 weeks with one or more standard antidepressants, with no change in antidepressant dosage or drug for at least 4 weeks; likely to be maintained on this treatment and dosage for the duration of the study
  • 4. Diagnosis of major depressive disorder (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM IV])
  • 5. Male or female, of any race, aged 18-65

排除标准

  • Not provided at time of registration

研究者

发起方
axdale Ltd (UK)

相似试验

已完成
不适用
A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate [EPA]) in patients with a new or recurrent episode of depressioDepressionMental and Behavioural DisordersDepressive episode
ISRCTN63565713axdale Ltd (UK)
已完成
不适用
A multicentre, double-blind, randomised, parallel group, placebo-controlled, dose-ranging pilot study of ethyl-eicosapentaenoate (ethyl-EPA) in patients with schizophreniaMental and Behavioural DisordersSchizophrenia
ISRCTN44218911axdale Ltd (UK)
已完成
不适用
A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate [EPA]) as adjunct therapy in patients who remain depressed following treatment with standard antidepressant therapyDepressionMental and Behavioural DisordersDepressive episode
ISRCTN38354847axdale Ltd (UK)
进行中(未招募)
不适用
Clinical study to investigate the efficacy and safety of an ointment that increases the blood circulation in the skin, containing 2.5% Nicoboxil and 0.4% Nonivamide, in comparison to ointments that contain only one of both compounds, or none of them (placebo) for the treatment of acute low back paiAcute low back pain
EUCTR2011-003890-27-DEBoehringer Ingelheim Pharma GmbH & Co. KG
进行中(未招募)
1 期
Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthmaAsthma
EUCTR2013-002345-11-GBAstraZeneca AB1,134